Sameer Jain

Dr. Sameer Jain

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2019 in Brain Sciences
Verified
Journal Article
Open access
PDF file
TDTimothy R. Deer
Timothy R. Deer
SJSameer Jain
Sameer Jain
CHCorey Hunter
Corey Hunter
KCKrishnan Chakravarthy
Krishnan Chakravarthy
The field of neuromodulation has seen unprecedented growth over the course of the last decade with novel waveforms, hardware advancements, and novel chronic pain indications. We present here an updated review on spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation. We focus on mechanisms of action, clinical indications, and future areas of research. We also present current drawbacks with current stimulation technology and suggest areas of future advancements. Given the current shortage of viable treatment options using a pharmacological based approach and conservative interventional therapies, neuromodulation presents an interesting area of growth and development for the interventional pain field and provides current and future practitioners a fresh outlook with regards to its place in the chronic pain treatment paradigm.

1 July 2020 in Pain Management
Verified
Journal Article
Open access
SJSameer Jain
Sameer Jain
TDTimothy Deer
Timothy Deer
DSDawood Sayed
Dawood Sayed
PCPooja Chopra
Pooja Chopra
SWSayed Wahezi
Sayed Wahezi
SGStanley Golovac
Stanley Golovac
Lumbar spinal stenosis is a common degenerative spine condition. In properly selected patients, minimally invasive lumbar decompression (mild®) may be an option to improve outcomes. This review pro...

21 September 2018 in Pain Management
Verified
Journal Article
Closed access
SJSameer Jain
Sameer Jain
HYHsiangkuo Yuan
Hsiangkuo Yuan
NSNicole Spare
Nicole Spare
SSStephen D Silberstein
Stephen D Silberstein
Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies. Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathogenesis of migraine. In recent years, research has been dedicated to the development of monoclonal antibodies against CGRP and CGRP receptors for the treatment of migraine. This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been published demonstrating the efficacy and safety of erenumab in the prevention of migraine.

14 March 2019 in Current Treatment Options in Neurology
Verified
Journal Article
Closed access
PDF file
SJSameer Jain
Sameer Jain
SSStephen D Silberstein
Stephen D Silberstein

21 September 2018 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
SJSameer Jain
Sameer Jain
MFMichael A Fishman
Michael A Fishman
CWChengyuan Wu
Chengyuan Wu
Spinal cord stimulation has been an effective therapy for treatment of chronic low back pain over the last four decades. Over the years, there have been significant technological advances in the neuromodulation devices. Externally powered neuromodulation devices, that do not require an internal pulse generator (IPG) implantation, have recently been approved for treatment of chronic pain and the data on potential pitfalls and unforeseen complications with these devices is minimal. Here, we report a case of a 60-year-old woman with chronic back pain who underwent the implantation of one of such devices and developed complication that required neurosurgical intervention. The epidural stimulator leads in the patient migrated cranially to the T2 level that required extensive neurosurgical exploration. We believe this is the first reported case of such significant cranial epidural lead migration with the use of neurostimulation devices and demands more research into the safety of externally powered neurostimulation devices.

22 March 2022 in Pain Management
Verified
Journal Article
Closed access
ADAbhigyan Datta
Abhigyan Datta
SGSahil Gupta
Sahil Gupta
SMShashi Maryala
Shashi Maryala
VAVikram Aggarwal
Vikram Aggarwal
PCPooja Chopra
Pooja Chopra
SJSameer Jain
Sameer Jain
In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled tria... Plain language summary In this review, the authors give an overview of erenumab, an injectable medication used to prevent migraine headaches. Erenumab has been proven to be significantly effective ...